Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

Gooley, Ted; Leisenring, Wendy M.; Crowley, John; Storer, Barry E.

doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.3.co;2-f

Cited by 1,138 publications

(1,376 citation statements)

References 0 publications

Supporting

Mentioning

1,347

Contrasting

Unclassified

Order By: Relevance

“…Cumulative incidence function was calculated for neutrophil recovery, platelet engraftment, acute and chronic GvHD in a competing-risk setting, where death was considered the competing event 8 . Gray test was used for univariate comparisons.…”

Section: Resultsmentioning

confidence: 99%

Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis

Chiesa

Ruggeri

Paviglianiti

et al. 2016

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis

Chiesa

Ruggeri

Paviglianiti

et al. 2016

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

“…26 For estimating the cumulative incidence of GVHD, death was considered as a competing event. Overall (OS) and leukemia-free (LFS) survivals (starting from date of transplant) were calculated using the Kaplan-Meier estimates; the log-rank test was used for univariate comparisons.…”

Section: Resultsmentioning

confidence: 99%

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

et al. 2012

View full text Add to dashboard Cite

This report investigated the impact of graft-versus-host disease (GVHD) on transplantation outcomes in 1859 acute myeloid leukemia patients given allogeneic peripheral blood stem cells after reduced-intensity conditioning (RIC allo-SCT). Grade I acute GVHD was associated with a lower risk of relapse (hazards ratio (HR) ¼ 0.7, P ¼ 0.02) translating into a trend for better overall survival (OS; HR ¼ 1.3; P ¼ 0.07). Grade II acute GVHD had no net impact on OS, while grade III-IV acute GVHD was associated with a worse OS (HR ¼ 0.4, Po0.0.001) owing to high risk of nonrelapse mortality (NRM; HR ¼ 5.2, Po0.0001). In time-dependent multivariate Cox analyses, limited chronic GVHD tended to be associated with a lower risk of relapse (HR ¼ 0.72; P ¼ 0.07) translating into a better OS (HR ¼ 1.8; Po0.001), while extensive chronic GVHD was associated with a lower risk of relapse (HR ¼ 0.65; P ¼ 0.02) but also with higher NRM (HR ¼ 3.5; Po0.001) and thus had no net impact on OS. In-vivo T-cell depletion with antithymocyte globulin (ATG) or alemtuzumab was successful at preventing extensive chronic GVHD (Po0.001), but without improving OS for ATG and even with worsening OS for alemtuzumab (HR ¼ 0.65; P ¼ 0.001). These results highlight the role of the immune-mediated graft-versus-leukemia effect in the RIC allo-SCT setting, but also the need for improving the prevention and treatment of severe GVHD.

show abstract

“…Cumulative incidence curves were used to describe the cumulative mortality from colon cancer-specific deaths, treating the other causes of death as competing risk. 14 The Kaplan-Meier and cumulative incidence curves were started at 16 weeks after surgery. This starting time was the earliest time point that allowed us to define all ''time from surgery to adjuvant chemotherapy'' groups before the starting time: Deaths before this starting time were not included in the analysis.…”

Section: Resultsmentioning

confidence: 99%

Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada

Lima

Yasui

Scarfe

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND: Surgery followed by adjuvant chemotherapy has been standard treatment for stage III colon cancer since 1990. However, to date, clinical trials have not been conducted to determine the definitive outer time limit by which adjuvant chemotherapy should be received for optimal survival benefit. The objective of the current study was to assess the association between the receipt/timing of adjuvant chemotherapy and patient survival in clinical practice. METHODS: Residents of Alberta who were diagnosed with stage III colon adenocarcinoma in years 2000 to 2005 who underwent surgery were included in the study. Patients were identified from the Alberta Cancer Registry and were linked to hospital data and neighborhood-level socioeconomic data from the 2001 Canadian Census. Cox proportional hazards models were used to estimate hazard ratios of death according to the timing of chemotherapy. RESULTS: There were 1053 patients in the study; 648 (61%) initiated adjuvant chemotherapy within 16 weeks of surgery. There was no difference in overall survival or colon cancer-specific survival between those who received adjuvant chemotherapy from 8 to 12 weeks postsurgery compared with those who received it within 8 weeks. However, those who received chemotherapy 12 to 16 weeks after surgery and those who either received it >16 weeks after surgery or received no treatment had a 43% and 107% greater risk of dying, respectively, than those who received chemotherapy within 8 weeks of surgery (hazard ratio, 1.43 [95% confidence interval, 0.96-2.13] and hazard ratio, 2.07 [95% confidence interval, 1.56-2.76], respectively). Analyses were controlled for age, year, and region of residence at diagnosis; sex; neighborhood-level socioeconomic factors; and number of comorbidities. CONCLUSIONS: The results from this study were consistent with current guideline recommendations in Alberta that patients with stage III adenocarcinoma should receive chemotherapy within 12 weeks of surgery. Cancer 2011;117:3833-

show abstract

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

Cited by 1,138 publications

References 0 publications

Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis

Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada

Contact Info

Product

Resources

About